SCHEMBL3070833

SCHEMBL3070833

N=C(N)NC(=N)N(C1CCCCC1)C1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 1/20 0.38
NOS2 P35228 2/20 0.34
ALDH1A1 P00352 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
RECQL P46063 1/20 0.32
ADAM17 P78536 1/20 0.32
KMT2A Q03164 1/20 0.32
TSHR P16473 1/20 0.30
HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19371430 0.98 PHGDH (0.36) PHGDHNOS2ALDH1A1KDM4EMEN1
SCHEMBL11123952 0.82 PHGDH (0.36) PHGDHNOS2ALDH1A1KDM4EMEN1
SCHEMBL17777672 0.80 FAAH (0.41) PHGDHNOS2ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL7781707 0.80 F2 (0.38) ALDH1A1MEN1LMNAKMT2ATSHR
SCHEMBL28129360 0.79 F2 (0.37) NOS2ALDH1A1MEN1LMNAKMT2A
Hydrochloric Acid SCHEMBL1937538 0.79 FAAH (0.40) PHGDHNOS2ALDH1A1MEN1KMT2A
SCHEMBL16369759 0.77
SCHEMBL3074753 0.75 PHGDH (0.44) PHGDHNOS2ALDH1A1KDM4EMEN1
SCHEMBL4086315 0.74 PHGDH (0.40) PHGDHALDH1A1KDM4EMEN1LMNA
SCHEMBL3295728 0.72 EPHX1 (0.43) PHGDHALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200277255-A1 BIGUANIDE COMPOUND AND USE THEREOF IMMUNOMET THERAPEUTICS INC. 2020-09-03 US claimed
US-10626085-B2 Biguanide compound and use thereof IMMUNOMET THERAPEUTICS INC. (US) 2020-04-21 US claimed
US-20180044283-A1 BIGUANIDE COMPOUND AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2018-02-15 US claimed
EP-3222614-A2 BIGUANIDE COMPOUND AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-09-27 EP claimed
CN-107108536-A Biguanide compound and application thereof 伊谬诺米特医疗有限公司 2017-08-29 CN claimed
US-12264275-B2 Treatment liquid FUJIFILM CORPORATION (JP) 2025-04-01 US disclosed
US-20240002725-A1 COMPOSITION AND METHOD FOR TREATING SUBSTRATE FUJIFILM CORPORATION (JP) 2024-01-04 US disclosed
CN-117062940-A Composition and method for treating substrate 富士胶片株式会社 2023-11-14 CN disclosed
EP-3719105-B1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MAT USA INC (US) 2023-09-27 EP disclosed
US-11639487-B2 Cleaning formulation for removing residues on surfaces FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2023-05-02 US disclosed
US-11618867-B2 Cleaning formulation for removing residues on surfaces FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2023-04-04 US disclosed
US-20230101156-A1 TREATMENT LIQUID FUJIFILM CORPORATION (JP) 2023-03-30 US disclosed
US-20040016363-A1 CORROSION-INHIBITING COATING VENTURE LENDING & LEASING, IV, INC. 2004-01-29 US disclosed
WO-2004009869-A2 CORROSION-INHIBITING COATING FOR METAL SURFACES UNIVERSITY OF DAYTON (US) 2004-01-29 WO disclosed
US-20040011252-A1 Non-toxic corrosion-protection pigments based on manganese UNIVERSITY OF DAYTON 2004-01-22 US disclosed
US-20030234063-A1 Non-toxic corrosion-protection conversion coats based on cobalt DAYTON, UNIVERSITY OF 2003-12-25 US disclosed
US-20030230363-A1 Non-toxic corrosion-protection rinses and seals based on cobalt UNIVERSITY OF DAYTON 2003-12-18 US disclosed
WO-2003060191-A2 NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
WO-2003060192-A1 NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
WO-2003060019-A1 NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626085-B2 Biguanide compound and use thereof MKI67, GCG, GCKR PHGDH 1037/4885NOS2 361/4885ALDH1A1 1098/4885
US-20180044283-A1 BIGUANIDE COMPOUND AND USE THEREOF MKI67, GCG, GCKR PHGDH 1037/4885NOS2 361/4885ALDH1A1 1098/4885
US-20200277255-A1 BIGUANIDE COMPOUND AND USE THEREOF MKI67, GCG, GCKR PHGDH 1037/4885NOS2 361/4885ALDH1A1 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.